Antibiofilm and antimicrobial activity of curcumin-chitosan nanocomplexes and trimethoprim-sulfamethoxazole onAchromobacter, Burkholderia, andStenotrophomonasisolates

Montoya-Hinojosa, Edeer; Salazar-Sesatty, Humberto Antonio; Alvizo-Báez, Cynthia Aracely; Terrazas-Armendariz, Luis D; Luna-Cruz, Itza Eloisa; Alcocer‐González, Juan Manuel; Villarreal-Treviño, Licet; Flores-Treviño, Samantha

doi:10.1080/14787210.2023.2166933

Cited by 6 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that the mechanism of action of Cur-Chi-MNP occurs before biofilms are formed and not after the mature biofilms are established. Similar to our study, previous results indicated that higher antibacterial activity occurs on pre-formed biofilms compared to established biofilms (35). Our results also indicate that Cur-Chi-MNP have lesser antibiofilm activity (either at the inhibition or eradication stage) on CoNS, specifically S. epidermidis and S. lugdunensis.…”

Section: Accepted Manuscriptsupporting

confidence: 91%

See 1 more Smart Citation

Biofilm Eradication and Inhibition of Methicillin-Resistant Staphylococcus Clinical Isolates by Curcumin-Chitosan Magnetic Nanoparticles

Salazar-Sesatty,

Montoya-Hinojosa,

Villarreal-Salazar

et al. 2024

Jpn J Infect Dis

Self Cite

View full text Add to dashboard Cite

Biofilm-producing methicillin-resistant Staphylococcus aureus (MRSA) and coagulasenegative Staphylococci (MR-CoNS) are a clinical challenge for the treatment of healthcareassociated infections. As alternative antimicrobial options are needed, we aimed to determine the effect of curcumin-chitosan magnetic nanoparticles on the biofilm of staphylococcal clinical isolates. MRSA and CoNS clinical isolates were identified by MALDI-TOF mass spectrometry. Antimicrobial susceptibility testing was performed by broth microdilution. Nanoparticles were synthesized by co-precipitation of magnetic nanoparticles (MNP) and encapsulation by ionotropic gelation of curcumin (Cur) and chitosan (Chi). Biofilm inhibition and eradication by nanoparticles with and without the addition of oxacillin was assessed on staphylococcal strains. Cur-Chi-MNP showed antimicrobial activity on planktonic cells of MRSA and MR-CoNS strains and inhibited biofilm of MRSA. The addition of OXA to Cur-Chi-MNP increased biofilm inhibition and eradication activity against all Staphylococci strains (p=0.0007); higher biofilm activity was observed in early biofilm stages. Cur-Chi-MNP showed antimicrobial and biofilm inhibition activity against S. aureus. The addition of OXA increased biofilm inhibition and eradication activity against all Staphylococci strains. A combination treatment of Cur-Chi-MNP and OXA could be potentially used to treat staphylococcal biofilm-associated infections in its early stages before the establishment of biofilm bacterial cells.

show abstract

Section: Accepted Manuscriptsupporting

confidence: 91%

“…antibacterial activity (29). In a previous study, Cur-Chi-MNP showed lower antibacterial activity than Cur against non-fermenting Gram-negative Achromobacter xylosoxidans, Burkholderia cepacia complex, and Stenotrophomonas maltophilia clinical isolates (35).…”

Section: Accepted Manuscriptmentioning

confidence: 89%

Biofilm Eradication and Inhibition of Methicillin-Resistant Staphylococcus Clinical Isolates by Curcumin-Chitosan Magnetic Nanoparticles

Salazar-Sesatty,

Montoya-Hinojosa,

Villarreal-Salazar

et al. 2024

Jpn J Infect Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conversely, NPs containing bioactive natural polymers were studied by Montoya-Hinojosa et al [196] and Patel et al [197], by producing two different formulations containing chitosan. The first group encapsulated curcumin-chitosan-sodium tripolyphosphate (Cur-Chi-TPP) inside iron oxide magnetic nanoparticles (MNPs) and tested its efficacy in combination with trimethoprim-sulfamethoxazole (TMP-SXT) on different CF bacteria, i.e., Bcc, A. xylosoxidans and S. maltophilia, susceptible or resistant to TMP-SXT.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis

Scoffone,

Barbieri,

Irudal

et al. 2024

Antibiotics

View full text Add to dashboard Cite

People with cystic fibrosis (CF) suffer from recurrent bacterial infections which induce inflammation, lung tissue damage and failure of the respiratory system. Prolonged exposure to combinatorial antibiotic therapies triggers the appearance of multi-drug resistant (MDR) bacteria. The development of alternative antimicrobial strategies may provide a way to mitigate antimicrobial resistance. Here we discuss different alternative approaches to the use of classic antibiotics: anti-virulence and anti-biofilm compounds which exert a low selective pressure; phage therapies that represent an alternative strategy with a high therapeutic potential; new methods helping antibiotics activity such as adjuvants; and antimicrobial peptides and nanoparticle formulations. Their mechanisms and in vitro and in vivo efficacy are described, in order to figure out a complete landscape of new alternative approaches to fight MDR Gram-negative CF pathogens.

show abstract

“…In susceptible individuals, S. maltophilia can cause infections including meningitis, urinary tract infections, bloodstream infections, and pneumonia, with mortality rates from 29 to 70% [ 5 ]. This is largely attributable to the broad-spectrum drug resistance exhibited by this opportunistic pathogen, which encodes aminoglycoside modifying enzymes, multidrug efflux pumps, and β-lactamases, in addition to exhibiting low levels of intrinsic permeability [ 6 , 7 ]. S. maltophilia can also acquire drug resistance over the course of treatment.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study

Chen

Hua

Hong

et al. 2023

Ann. Intensive Care

View full text Add to dashboard Cite

Purpose Stenotrophomonas maltophilia is a Gram-negative pathogen that most commonly causes hospital-acquired infections that can be extremely challenging to treat, contributing to underrecognized mortality throughout the world. The relative benefits of monotherapy as compared to combination therapy in patients diagnosed with S. maltophilia pneumonia, however, have yet to be established. Methods Data from 307 patients diagnosed with S. maltophilia hospital-acquired pneumonia (HAP) across four Chinese teaching hospitals from 2016 to 2022 were retrospectively analyzed. Results Of the analyzed patients, 55.7% (171/307) were administered combination definitive therapy, with a 30-day all-cause mortality rate of 41.0% (126/307). A propensity score weighting analysis revealed that compared with monotherapy, combination definitive therapy was associated with a comparable 30-day mortality risk in the overall patient cohort (OR 1.124, 95% CI 0.707–1.786, P = 0.622), immunocompetent patients (OR 1.349, 95% CI 0.712–2.554, P = 0.359), and patients with APACHE II scores < 15 (OR 2.357, 95% CI 0.820–6.677, P = 0.111), whereas it was associated with a decreased risk of death in immunocompromised patients (OR 0.404, 95% CI .170–0.962, P = 0.041) and individuals with APACHE II scores ≥ 15 (OR 0.494, 95% CI 0.256–0.951, P = 0.035). Conclusion The present data suggest that when treating S. maltophilia-HAP, immunocompromised patients and individuals with APACHE II scores ≥ 15 may potentially benefit from combination therapy.

show abstract

Antibiofilm and antimicrobial activity of curcumin-chitosan nanocomplexes and trimethoprim-sulfamethoxazole onAchromobacter, Burkholderia, andStenotrophomonasisolates

Cited by 6 publications

References 36 publications

Biofilm Eradication and Inhibition of Methicillin-Resistant <i>Staphylococcus</i> Clinical Isolates by Curcumin-Chitosan Magnetic Nanoparticles

Biofilm Eradication and Inhibition of Methicillin-Resistant <i>Staphylococcus</i> Clinical Isolates by Curcumin-Chitosan Magnetic Nanoparticles

New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis

Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study

Contact Info

Product

Resources

About